Interleukin-6 (IL-6) is a marker of futile reperfusion in patients with acute ischemic stroke (AIS) and large vessel occlusion (LVO) treated with mechanical thrombectomy (MT).
Why this matters
IL-6 levels were previously observed to be associated with stroke severity and outcome, but its prognostic and predictive value in clinical practice remains unclear.
The rate of futile reperfusion after MT for AIS with LVO was reported to be ~54%, attributed to both thrombotic and inflammatory pathways; the role of IL-6 has not been studied.
This study provides evidence of IL-6 as a factor that influences outcomes after reperfusion, and potentially helps in clinical decision-making.